Skip to main content
HRMYHarmony Biosciences Holdings, IHold7.4·$38.01-0.37%

Harmony Biosciences Holdings, I (HRMY) Q2 2026 earnings — TrendMatrix coverage

BEAT+30.6% vs estimateEPS $1.50 vs $1.15 estVerdict HoldBuy (Wait)

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$1.50
Estimate
$1.15
Surprise
+30.6%
Revenue (period 2026-06-30)
$261.3M
Score at report (before → after)
7.07.0/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Harmony Biosciences Holdings, I (HRMY) beat the $1.15 estimate with diluted EPS of $1.50 — a large 30.6% upside surprise. TrendMatrix's engine moved from Hold (7.0/10) to Buy (Wait) at 7.0/10 after the report.

Current read · as of 2026-08-24

Where TrendMatrix's rating stands now

TrendMatrix currently rates HRMY Hold at 7.4/10.

2 of the last 4 quarters beat the estimate; this quarter's +30.6% surprise compares with a -1.6% four-quarter average. Next scheduled report: 2026-11-03.

What supports the rating

  • Strong overall score: 7.4/10
  • High-quality business

What argues against it

  • Concentration risk — Product: WAKIX
  • Concentration risk — Supplier: sole-source suppliers and manufacturers
  • Thin upside margin: 5.6%

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$38.01
Price target
$40.11
Stop
$35.65
Upside to target
+5.5%
Reward-to-risk
0.6:1

The stock trades at 12.3× trailing but 5.7× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-08-24 — shown for context, not personalized investment advice.

Healthcare context

HRMY at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$2.22B
P/E (fwd)
5.7
P/E (ttm)
12.3
52-week range
$25.52$40.87
Off 52-week high
7.0%
RSI (14)
45
Volume vs avg
0.08×
Score today
7.4/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks HRMY Earnings Q2 2026 earnings